Digital healthcare blends software Economics with the defensive Demand of the health sector, and London's junior market hosts several of its more interesting operators. As September 2026 results land, hospital-software group Craneware, cognitive-assessment specialist Cambridge Cognition and digital mental-health provider Kooth show three routes into the theme — each with Recurring Revenue at its core but very different scale, geography and momentum.
FTSE AIM All-Share Digital Healthcare Outlook for September 2026
Health systems on both sides of the Atlantic are under sustained pressure to do more with constrained budgets, and technology is central to how they respond. In the United States, hospitals are focused on revenue integrity, cost recovery and the economics of drug pricing; in the United Kingdom, the NHS continues a long push towards digital tools that expand capacity without proportionate increases in staff. That structural demand underpins the digital-healthcare theme, but it is mediated by procurement cycles, reimbursement and — for the software businesses — the pace at which contracted work converts into recognised revenue.
Recurring, subscription-style revenue is the prize in this sector. Companies that can embed their software into clinical or financial workflows enjoy high retention and predictable cash flows, which the market rewards with premium ratings. The corollary is that any disruption to renewals, contract timing or a key funding programme can move these shares sharply, because so much of their value rests on the durability of future revenue.
Artificial intelligence is an increasingly prominent thread, whether in interpreting clinical data, automating administrative processes or enhancing assessment tools. It offers genuine efficiency gains but also raises the bar on regulatory scrutiny, particularly where software influences clinical decisions. The three companies profiled here — a scaled, profitable US-focused software provider, a small but improving cognitive-science Business and a profitable digital mental-health operator — capture the range of Maturity within the FTSE AIM All-Share digital-healthcare theme. A note on constituents: this article substitutes Kooth for a company named in the original sector brief that no longer fits the FTSE AIM All-Share investability profile; the rationale appears in the accompanying completion record.
Craneware plc (LSE:CRW)
Craneware (LSE:CRW) is a healthcare software company that helps US hospitals and health systems improve financial performance, operational efficiency and regulatory compliance. Its platform spans revenue-cycle management, cost and Margin analytics, and — importantly — support for the 340B drug-pricing programme, a US federal scheme that lets qualifying providers buy certain medicines at discounted prices. The company sells multi-year software subscriptions, giving it a large base of recurring revenue and high customer retention, and it reports in US dollars while its shares are quoted in London.
This is the most mature and profitable of the three businesses examined here, generating substantial adjusted EBITDA and cash. Its scale and recurring-revenue model place it towards the lower-risk end of the AIM digital-health spectrum, though recent trading has highlighted that it is not immune to shifts in the US healthcare policy environment.
Latest trading and the 340B issue
In an FY26 trading update on 3 July 2026, covering the year to 30 June 2026, Craneware indicated revenue of approximately US$205–208 million and adjusted EBITDA of around US$65–67 million, both broadly in line with the prior year but below market expectations. The shortfall was attributed to the timing of 340B drug conversion: while the company had a large pipeline of 340B-qualifying opportunities — with outstanding qualifying drug purchases of roughly US$500 million — the pace at which these translated into eligible purchases slowed materially in the final weeks of the year as pharmaceutical manufacturers expanded restrictions on 340B-priced medicines. Some enterprise contracts were also deferred into FY27.
Management framed the setback as a short-term timing impact rather than a weakening of underlying demand, noting that customer retention and demand remained strong and cash generation robust. Full-year results were expected in September 2026. The episode is a useful reminder that even a high-quality, sticky software business can be exposed to policy and third-party behaviour beyond its control.
Strategy, catalysts and risks
The quality of Craneware's business rests on its recurring-revenue model and the depth of its integration into hospital workflows. Multi-year subscriptions and high retention give it visibility and cash generation that most AIM peers cannot match, and this is precisely why the 340B timing issue is a matter of deferral rather than lost demand: the underlying contracts and relationships remain intact, and the pipeline of qualifying drug purchases has not disappeared. The market's sharp reaction to the update reflected the premium rating the shares carry, under which even a timing-related miss is penalised heavily.
Strategically, Craneware is broadening from software and analytics into what it describes as technology-enabled operational transformation — helping providers actually realise the savings and revenue its software identifies. This moves it further up the value chain and, if successful, could deepen customer relationships and expand its addressable market.
Identifiable catalysts include the full-year results due in September 2026, the conversion of the deferred 340B purchases and enterprise contracts in FY27, and progress on the operational-transformation strategy. The key risks are US healthcare policy — particularly the evolving treatment of the 340B programme by manufacturers and regulators — customer concentration among large health systems, currency translation for sterling-based investors, and the premium rating the shares have historically carried, which leaves limited room for disappointment. As at 13 September 2026 the shares traded at about 1,320p, capitalising the company at roughly £447 million on London market data.
Cambridge Cognition Holdings plc (LSE:COG)
Cambridge Cognition (LSE:COG) develops digital tools to measure and monitor brain health. Its established business supplies cognitive-assessment software — most notably the CANTAB battery — to pharmaceutical companies and academic researchers running Clinical Trials in neurology, psychiatry and related fields, and it has been extending into healthcare and consumer wellness applications, including speech-based assessment through its Winterlight platform. Revenue comes from a mix of licence, service and increasingly recurring income.
This is a small company by market value, and it has historically operated close to breakeven, but its recent results point to improving financial discipline and a broadening commercial base.
Latest results and balance sheet
In its first-half 2026 results, Cambridge Cognition reported revenue up 16% to £5.0 million, including initial sales from new healthcare and consumer-wellness pilots. New sales orders were £6.0 million in the half, and the order book stood at £16.1 million, with contracted orders indicating at least £10.0 million of full-year revenue. The adjusted EBITDA loss narrowed to around £0.3 million, and the company generated positive operating cash flow. Borrowings were cut to £0.2 million by June and fully repaid after the period end, leaving the company in a net cash, debt-free position; a £2.5 million Equity placing in July 2026 was raised to fund regulatory clearances in Europe and the US, paediatric product development and speech-recognition enhancements on the Winterlight platform.
The combination of double-digit revenue growth, a healthy order book, a narrowing loss and the clearance of Debt marks a meaningful improvement, though the £2.5 million placing is a reminder that the company still turns to the market to fund expansion.
Strategy, catalysts and risks
Cambridge Cognition is pursuing a deliberate expansion beyond its core clinical-trials business into digital brain-health applications in healthcare and consumer wellness. Recent agreements — with a major European private healthcare provider for its CANTAB Pathway platform, a brain-health research Partnership with ŌURA and a commercialisation deal with Ivory in India — illustrate that strategy in action.
Identifiable catalysts include conversion of the £16.1 million order book into revenue, delivery against the guided £10.0 million-plus full-year figure, regulatory clearances in Europe and the US, and progress on the new healthcare and wellness partnerships. The risks are those of a micro-cap: reliance on pharmaceutical R&D budgets for the core business, the execution risk in entering new markets, the potential for further equity dilution, and thin share liquidity. As at 14 September 2026 the shares traded at about 28p, for a Market Capitalisation of roughly £15 million on London market data — a scale at which trading can be volatile.
Kooth plc (LSE:KOO)
Kooth (LSE:KOO) is a digital mental-health company that provides online counselling, self-help and wellbeing support, historically to young people in the United Kingdom through the NHS and local authorities, and increasingly in the United States. Its largest single engagement has been the Soluna service in California, delivered under the state's Children and Youth Behavioral Health Initiative, and it is pursuing what it calls a 'State Alliance' model to embed its platform within public health and education systems.
Kooth is included here as a substitute for a company named in the original sector brief whose scale and Liquidity no longer fit the FTSE AIM All-Share profile. It is a commercial, revenue-generating and — increasingly — profitable digital-health business, offering a useful contrast to the software and cognitive-science models of its peers.
Latest trading and financial position
In a half-year 2026 trading update, Kooth reported revenue of £30.8 million for the six months to 30 June 2026, down from £32.1 million a year earlier, a decline it attributed to the planned tapering of California product-development income and adverse foreign-exchange effects. Encouragingly, adjusted EBITDA was expected to rise materially to £5.0–5.4 million, from £1.6 million previously, reflecting stronger operational performance, and unaudited net cash increased to £23.1 million. Detailed half-year results were scheduled for September 2026.
The California programme, in its fourth year, had reached 187,000 Soluna registrations and featured in Governor Gavin Newsom's Children and Youth Behavioral Health Initiative. In the UK, Kooth was launching an integrated employment and mental-health pathfinder in the West Midlands and rolling out Soluna for students. The mix of falling headline revenue but sharply higher profitability and cash is the defining feature of the current period — a business becoming more efficient even as one large contract matures.
Strategy, catalysts and risks
Kooth's strategy centres on its State Alliance model — winning and deepening relationships with US states and UK public bodies to build a more diversified, recurring revenue base and reduce dependence on any single contract. The evolution of the California engagement beyond its initial development phase, and the addition of further states, are the key strategic tests. The current period, in which revenue dips while profitability and cash rise sharply, captures the transition well: the company is trading lower-margin development income for a leaner, more sustainable service model, and the market's assessment will hinge on whether it can replace that income with new, durable contracts.
Identifiable catalysts include the detailed half-year results in September 2026, news on the renewal or expansion of the California contract, new US state wins, and progress on UK pathfinders. The risks are significant: heavy reliance on the California contract has been a defining feature, and its maturation illustrates the customer-concentration risk; the business is exposed to US state budget cycles and political priorities, to currency movements, and to the challenge of replacing development income with sustainable service revenue. As at 14 September 2026 the shares traded at about 185p, for a market capitalisation of roughly £67 million on London market data.
How the Three FTSE AIM All-Share Stocks Compare
The three companies span the maturity curve of digital healthcare. Craneware is a scaled, profitable, cash-generative US hospital-software provider navigating a policy-driven timing setback. Cambridge Cognition is a small cognitive-science business with improving finances and a broadening market. Kooth is a profitable digital mental-health operator managing the maturation of a large contract while growing cash. The table summarises the key metrics; market capitalisations are approximate and point-in-time.
|
Company |
LSE Code |
Focus |
Market Cap (approx., date) |
Latest Revenue |
Profit Metric |
Cash |
Key Catalyst |
Key Risk |
|---|---|---|---|---|---|---|---|---|
|
Craneware |
CRW |
US hospital software / 340B |
~£447m (13 Sep 2026) |
US$205–208m FY26 (flat) |
Adj EBITDA US$65–67m |
Robust cash generation |
FY26 results; 340B conversion |
US health policy / 340B |
|
Cambridge Cognition |
COG |
Cognitive assessment |
~£15m (14 Sep 2026) |
£5.0m H1 2026 (+16%) |
Adj EBITDA loss ~£0.3m |
Net cash; debt repaid |
Order-book conversion |
R&D budgets / dilution |
|
Kooth |
KOO |
Digital mental health |
~£67m (14 Sep 2026) |
£30.8m H1 2026 (-4%) |
Adj EBITDA £5.0–5.4m |
Net cash £23.1m |
California renewal; new states |
Contract concentration / FX |
Sources: market data
What Could Drive the Sector Through the Rest of 2026?
US healthcare policy is the most immediate swing factor, and Craneware is the clearest example: the evolving stance of pharmaceutical manufacturers and regulators towards the 340B drug-pricing programme directly affects the timing of its revenue. How quickly the large Backlog of qualifying drug purchases converts will shape its FY27, and by extension sentiment towards the stock.
Public-sector budgets and priorities drive the demand for Kooth and, to a degree, Cambridge Cognition's healthcare ambitions. US state funding for youth mental health — exemplified by California's initiative — and UK public-sector appetite for digital services will determine how quickly these companies can diversify their contract bases. Political and budgetary shifts can accelerate or stall that process.
Recurring-revenue quality and cash generation will continue to differentiate the sector. The market has shown it will reward businesses that convert contracted work into predictable, profitable revenue — as Kooth's rising EBITDA and Cambridge Cognition's improving Cash Flow illustrate — and punish timing disappointments, as Craneware's share reaction to its 340B update showed. Investors are likely to keep prizing visibility and retention.
Finally, the broader adoption of AI and digital tools in healthcare, together with the associated regulatory frameworks, forms a supportive but demanding backdrop. Clearances in Europe and the US, of the kind Cambridge Cognition is funding, are enablers of growth, while the general direction of health-technology spending underpins the theme for all three.
Potential Catalysts to Watch
For Craneware, the near-term catalysts are the full-year results due in September 2026, the pace of 340B drug-purchase conversion and deferred enterprise-contract signings in FY27, and progress on the operational-transformation strategy.
For Cambridge Cognition, watch for conversion of the £16.1 million order book, delivery against guided full-year revenue of at least £10.0 million, regulatory clearances in Europe and the US, paediatric and Winterlight speech-recognition milestones, and traction from the ŌURA and Ivory partnerships.
For Kooth, the key events are the detailed half-year results in September 2026, developments on the California contract, new US State Alliance wins, and progress on UK pathfinder programmes. As always, these are potential rather than certain outcomes, and their effects on the shares could be positive or negative.
Key Risks Investors Should Consider
Policy and concentration risk is most visible at Craneware, where the 340B programme and a customer base of large US health systems create exposure to decisions outside the company's control, as the FY26 timing shortfall demonstrated. For Kooth, the reliance on the California contract has been a defining feature, and its maturation underlines the customer-concentration and public-budget risks inherent in its model.
Financing and execution risk is most acute for Cambridge Cognition, the smallest of the three, which has returned to the market for a £2.5 million placing to fund expansion and depends on pharmaceutical R&D spending for its core business; entering new healthcare and consumer markets carries meaningful execution risk. Even for the profitable names, converting contracted work into recognised revenue on the expected timetable is not guaranteed.
Currency movements affect all three, given significant US-dollar exposure against sterling-quoted shares. Additional considerations include the premium ratings that quality software names can carry, competition across each niche, and — for the smaller companies — thinner share liquidity and greater volatility. None of these businesses is free of material downside scenarios, and the balance of risk differs markedly between them.
Conclusion
Craneware, Cambridge Cognition and Kooth offer three distinct routes into AIM digital healthcare. Craneware is the scaled, profitable software provider — high-quality and cash-generative, but currently working through a policy-driven timing setback in its 340B business. Cambridge Cognition is the small, improving cognitive-science company, growing revenue and clearing debt while investing in new markets. Kooth is the profitable digital mental-health operator, lifting EBITDA and cash even as its flagship California contract matures.
The sector's structural demand is supportive, but the specific drivers differ: 340B conversion and US policy for Craneware, order-book delivery and clearances for Cambridge Cognition, and contract Diversification for Kooth. Through the remainder of 2026, Market Participants are likely to focus on Craneware's full-year results and 340B recovery, Cambridge Cognition's order-book conversion, and Kooth's California renewal and new state wins. Each carries distinct risks, and readers should weigh the catalysts against those risks according to their own circumstances. No recommendation to buy, sell or hold is made or implied.






Please wait processing your request...